ClinicalTrialsFinder
RecruitingPhase 3NCT07262476

Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease

A Phase III, Multicenter, Open-Label Extension Study to Evaluate the Efficacy and Safety of MHB018A Injection in Subjects With Thyroid Eye Disease

Sponsor

Minghui Pharmaceutical (Hangzhou) Ltd

Enrollment

258 participants

Start Date

Jan 9, 2026

Study Type

INTERVENTIONAL

Conditions

Thyroid Eye Disease (TED)

Summary

This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MHB018A injection for people with thyroid eye disease (ted). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMHB018A injection

MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

Locations(1)

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07262476

Related Trials

A Clinical Study of Cizutamig in Thyroid Eye Disease

NCT075972001 location

Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

NCT075479301 location

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

NCT074007571 location

MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

NCT072571851 location

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease

NCT065697581 location